Varian Medical Systems Investor Presentation — October 2017

Document content

Vice President Investor Relations

Mike.Bruff@Varian.comOctober 25, 2017

FORWARD -LOOKING STATEMENTS

Except forhistorical information, this presentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements concerning industry outlook, including

growth drivers, future trends incancer incidence and trends incancer treatment needs, demand, innovation and growth opportunities ;Varian Medical System, Inc.’s(”Varian” orthe “company”) future orders,

revenues, backlog orearnings growth ;future financial results ;market acceptance ofortransition tonew products ortechnology such asour EdgeTMradiosurgery system, TrueBeam®,HyperArcTM,360 OncologyTM,

HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery and proton therapy, and any statements using the terms “could”, “believe”, “expect”, “outlook”, “anticipate”, ”vision”, “estimate”, “future”,

“horizon”, “aiming”, “driving”, “target” orsimilar statements areforward -looking statements that involve risks and uncertainties that could cause thecompany’s actual results todiffer materially from those anticipated .

Such risks and uncertainties include global economic conditions and changes totrends forcancer treatment regionally ;theimpact ofchanges totheAffordable Health Care forAmerica Act(including excise taxes on

medical devices) and any further healthcare reforms (including changes toMedicare and Medicaid), and/or changes tothird -party reimbursement levels ;currency exchange rates and taxrates ;demand forthe

company’s products ;thecompany’s ability todevelop, commercialize, and deploy new products ;thecompany’s ability tomeet Food and Drug Administration (FDA) and other regulatory requirements forproduct

clearances ortocomply with FDA and other regulatory regulations orprocedures, changes inthe regulatory environment, including with respect toFDA requirements ;the company’s assessment ofthe goodwill

associated with itsparticle therapy business, challenges associated with thesuccessful commercialization ofthecompany’s particle therapy business ;therisks associated with providing financing fortheconstruction and

start -upoperations ofproton therapy centers ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive

products and pricing ;thepotential loss ofkeydistributors orkeypersonnel ;challenges topublic tender awards and theloss ofsuch awards orother orders ;and theother risks listed from time totime inthecompany’s

filings with the Securities and Exchange Commission, which bythis reference areincorporated herein .The company assumes noobligation toupdate orrevise the forward -looking statements inthis presentation